Price David A, Scullard George, Oxenius Annette, Braganza Ruth, Beddows Simon A, Kazmi Shamim, Clarke John R, Johnson Gabriele E, Weber Jonathan N, Phillips Rodney E
The Peter Medawar Building for Pathogen Research and the Nuffield Department of Clinical Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, United Kingdom.
J Virol. 2003 May;77(10):6041-9. doi: 10.1128/jvi.77.10.6041-6049.2003.
Many individuals chronically infected with human immunodeficiency virus type 1 (HIV-1) experience a recrudescence of plasma virus during continuous combination antiretroviral therapy (ART) due either to the emergence of drug-resistant viruses or to poor compliance. In most cases, virologic failure on ART is associated with a coincident decline in CD4(+) T lymphocyte levels. However, a proportion of discordant individuals retain a stable or even increasing CD4(+) T lymphocyte count despite virological failure. In order to address the nature of these different outcomes, we evaluated virologic and immunologic variables in a prospective, single-blinded, nonrandomized cohort of 53 subjects with chronic HIV-1 infection who had been treated with continuous ART and monitored intensively over a period of 19 months. In all individuals with detectable viremia on ART, multiple drug resistance mutations with similar impacts on viral growth kinetics were detected in the pol gene of circulating plasma virus. Further, C2V3 env gene analysis demonstrated sequences indicative of CCR5 coreceptor usage in the majority of those with detectable plasma viremia. In contrast to this homogeneous virologic pattern, comprehensive screening with a range of antigens derived from HIV-1 revealed substantial immunologic differences. Discordant subjects with stable CD4(+) T lymphocyte counts in the presence of recrudescent virus demonstrated potent virus-specific CD4(+) and CD8(+) T lymphocyte responses. In contrast, subjects with virologic failure associated with declining CD4(+) T lymphocyte counts had substantially weaker HIV-specific CD4(+) T lymphocyte responses and exhibited a trend towards weaker HIV-specific CD8(+) T lymphocyte responses. Importantly the CD4(+) response was sustained over periods as long as 11 months, confirming the stability of the phenomenon. These correlative data lead to the testable hypothesis that the consequences of viral recrudescence during continuous ART are modulated by the HIV-specific cellular immune response.
许多长期感染1型人类免疫缺陷病毒(HIV-1)的个体在持续联合抗逆转录病毒治疗(ART)期间会出现血浆病毒复发,这要么是由于耐药病毒的出现,要么是依从性差所致。在大多数情况下,ART治疗的病毒学失败与CD4(+) T淋巴细胞水平的同时下降有关。然而,一部分不一致的个体尽管出现病毒学失败,但CD4(+) T淋巴细胞计数仍保持稳定甚至增加。为了探究这些不同结果的本质,我们对53名慢性HIV-1感染受试者进行了一项前瞻性、单盲、非随机队列研究,这些受试者接受了持续ART治疗,并在19个月的时间里进行了密集监测,评估了病毒学和免疫学变量。在所有ART治疗期间可检测到病毒血症的个体中,在循环血浆病毒的pol基因中检测到了对病毒生长动力学有类似影响的多种耐药突变。此外,C2V3 env基因分析表明,在大多数可检测到血浆病毒血症的个体中,序列表明使用了CCR5共受体。与这种同质的病毒学模式形成对比的是,用一系列源自HIV-1的抗原进行的全面筛查显示出显著的免疫学差异。在病毒复发时CD4(+) T淋巴细胞计数稳定的不一致受试者表现出有效的病毒特异性CD4(+)和CD8(+) T淋巴细胞反应。相比之下,与CD4(+) T淋巴细胞计数下降相关的病毒学失败受试者的HIV特异性CD4(+) T淋巴细胞反应明显较弱,并且HIV特异性CD8(+) T淋巴细胞反应有减弱的趋势。重要的是,CD4(+)反应可持续长达11个月,证实了该现象的稳定性。这些相关数据得出了一个可检验的假设,即持续ART期间病毒复发的后果受HIV特异性细胞免疫反应的调节。